KalVista Pharmaceuticals Inc.

Join this Action
Practice Area:
Stock Symbol: KALV
Case Status: Investigations

Ademi LLP is investigating KalVista (NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Chiesi Group.

KalVista stockholders will receive $27.00 per share in cash, representing approximately $1.9 billion in equity value. KalVista insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for KalVista by imposing a significant penalty if KalVista accepts a competing bid. We are investigating the conduct of the KalVista board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

Join this Action